Table 3.
Gender differences in treatment interruption due to adverse events.
| Females, N = 173 (%) | Males, N = 235 (%) | P value | |
|---|---|---|---|
| Chronic or recurring genital yeast infections | 37 (21.4) | 29 (12.3) | 0.020 |
| Persistent or recurring urinary tract infections | 7 (4.0) | 4 (1.7) | 0.216 |
| Other adverse eventsa | 10 (5.8) | 11 (4.7) | 0.655 |
| Overall | 54 (31.2) | 44 (18.7) | 0.005 |
aPolyuria, nausea, hypotension, dizziness, acute coronary event, worsening of glycemic control, and rapid deterioration of renal function. Statistical analysis was performed using Fisher's exact test.